Companies must constantly evolve to stay relevant in the pharmaceutical industry, and Teva Pharmaceutical Industries is in the midst of its own transformation. Brokers from Vaulltier dive into this topic, noting that every single Wall Street analyst polled by CNN Business currently carries a buy rating on the stock, with 12-month price targets implying 28% to 60% upside from current levels.

That kind of unanimous bullishness stands in sharp contrast to the stock’s recent history. Teva is down 40% over the past decade, yet comeback stories like this one sometimes produce the biggest returns.

Shifting Away From Low-Margin Generics

Teva has historically built its business around generics and biosimilars, categories known for high volume but thin profit margins. In recent years, however, leadership has deliberately shifted strategy toward developing novel branded drugs, a move that carries greater risk but significantly higher profit potential when successful.

That transition is already showing up in the numbers. Generic and biosimilar revenue declined 28% year over year to $612 million in the first quarter, now accounting for just 40% of total sales, a notable reduction in reliance on the company’s traditional core.

Looking ahead, management expects biosimilars to remain a growth driver, even as standard generics continue to shrink as a percentage of the overall business. This reflects a broader repositioning: moving away from commoditised products toward more differentiated therapies, where pricing power and margins tend to be stronger.

The shift underscores a fundamental transformation in Teva’s business model from a volume-driven generics manufacturer to a more innovation-focused pharmaceutical company with future performance increasingly tied to the success of its branded drug pipeline.

Branded Drugs Are Driving Real Momentum

Teva’s top-selling drug, Austedo, grew 41% to $559 million in the quarter, and management expects it to reach $2.4 billion to $2.55 billion in full-year sales, up from $2.26 billion in 2025. That single drug alone illustrates how meaningfully the branded portfolio is scaling.

Several smaller branded products are growing even faster on a percentage basis. Ajovy climbed 64% to $87 million, Uzedy surged 62% to $63 million, and Copaxone grew 16% to $62 million, showing broad-based momentum across the branded lineup.

Smaller Revenue, But Much Higher Quality

Total revenue is expected to decline from $17.3 billion in 2025 to a range of $16.4 billion to $16.8 billion this year, but that headline figure masks a more important shift in the underlying business. The mix is moving toward higher-margin products, meaning each dollar of revenue is becoming more valuable.

That transformation is reflected in profitability targets. Management is guiding for operating margins to reach 30% by 2027, a substantial improvement from just 12.5% last year, signalling a sharp pivot toward a more efficient and profitable model.

Supporting that transition, the biosimilars pipeline is projected to generate $800 million in sales by 2027, helping to offset the continued erosion in traditional generics.

Taken together, the outlook points to a company prioritising quality of earnings over sheer scale, with margin expansion and product mix now the key drivers of long-term performance rather than top-line growth alone.bb

Building the Pipeline Through Acquisition

Teva is reinforcing its strategic shift toward branded medicines with targeted pipeline expansion. The $700 million acquisition of Emalex Biosciences adds ecopipam, a late-stage treatment for Tourette’s syndrome in children, to its portfolio. Importantly, the company has already filed a New Drug Application (NDA) with the FDA, supported by positive Phase 3 clinical results, signalling that this asset could move toward commercialisation in the near to medium term.

This move highlights a broader pattern: management is actively investing in new growth drivers rather than relying solely on existing flagship products like Austedo. By adding innovative therapies with potential pricing power, Teva is positioning itself to accelerate revenue mix improvement and margin expansion.

The Emalex deal underscores that the branded strategy is not just a long-term vision but an ongoing, execution-driven transition, with pipeline additions playing a critical role in sustaining growth beyond the current product lineup.

Why the Price Targets Look Achievable

At roughly $31 per share, Teva trades at just 14× 2026 earnings estimates and only 10× 2027 estimates, a notably low valuation for a company with credible growth catalysts on the horizon. This discount largely reflects investor caution, but it also ties directly to the anticipated expansion in operating margins as higher-value branded drugs take a larger share of the business.

If management delivers on its targets, the upside becomes clearer. Even a modest re-rating to 15× 2027 earnings would imply a share price above Wall Street’s median target of $40, suggesting meaningful potential from current levels.

The broader investment case rests on a compelling combination: low starting valuation, improving profitability, and a growing portfolio of branded products. 

If execution remains on track, particularly around margin expansion and pipeline delivery, the current gap between valuation and fundamentals could narrow significantly, bringing bullish analyst expectations well within reach.